Current Studies in Lymphoma (Non-Hodgkin's Lymphoma)

NU 04H4
A Phase I/II Trial of Combination Bortezomib (VELCADE) and Gemcitabine Therapy for Patients with Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

Coordinator: David
NOTE: Please contact coordinator for update on currently enrolling dose level.
This study is suspended to accrual.
Protocol
HIPAA Authorization

NU Consent

VA Consent

NU 02H8
A Phase I/II Trial of Redox Regulation in Patients with Relapsed or Refractory CD20 positive Non-Hodgkin's Lymphoma (NHL) Combining 90-Yttrium-Zevalin and the Redox-Modulating Agent, Motexafin Gadolinium (MGd)

Coordinator: David
NOTE: Please contact coordinator for update on currently enrolling dose level.
Protocol
HIPAA Authorization

NU Consent

VA Consent

NU 05H9
A Phase I/II Trial of Combined Weekly Bortezomib (VELCADE®) and Y-90-Ibritumomab Tiuxetan (Zevalin) in Patients with Relapsed or Refractory Follicular Lymphoma

Coordinator: David
NOTE: Please contact coordinator for update on currently enrolling dose level.
Protocol
HIPAA Authorization

NU Consent

NU 06H1
A Phase II Trial of Combination Bortezomib and Rituximab as Front-line Therapy for Low-grade Non-Hodgkin’s Lymphoma

Coordinator: Becky
Protocol
HIPAA Authorization

NU Consent

NU 06H2
A Multicenter Phase II Study Incorporating Doxil and Rituximab into the Magrath Regimen for HIV-Negative and HIV- Positive Patients with Newly Diagnosed Burkitt’s and Burkitt-like Lymphoma

Coordinator: Lindsey
Protocol
HIPAA Authorization

NU Consent

NU 05H11
Multi-Institutional Non-Hodgkin's Lymphoma Outcomes Project within the National Comprehensive Cancer Network

Coordinator: Jordan, Eren
Protocol
HIPAA Authorization

NU Consent

ECOG 2402
A Phase II Study of Cyclosporine in the Treatment of Angioimmunoblastic T-Cell Lymphoma

Coordinator: Simbi
Protocol
HIPAA Authorization

NU Consent Form

VA Consent Form

ECOG 3402
A Phase II Trial of R-CHOP Followed By Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma

Coordinator: David
Protocol
HIPAA Authorization

NU Consent Form

VA Consent Form

ECOG 3404
Response-Adapted Therapy for Aggressive non-Hodgkin's Lymphomas based on early [18F] FDG-PET Scanning

Coordinator: Lindsey
Protocol
HIPAA Authorization

NU Consent Form

CALGB 50303
Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH- R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas

Coordinator: Simbi
Protocol
HIPAA Authorization

NU Consent Form

DRUG 013
A Phase I Study of L-000891675 (MK-0752), a Notch Inhibitor, for Adult and Pediatric Patients With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and Lymphoma

Coordinator: Simbi
Protocol
HIPAA Authorization

NU Consent Form

DRUG 3129K3-101-WW
A Phase I/II Study of CMC-544 Administered in Combination with Rituximab in Subjects With Follicular or Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Coordinator: Simbi
Protocol
HIPAA Authorization

NU Consent Form

DRUG AT-101-CS-005
A Phase II, Open Label, Multicenter Study of Single-Agent AT-101 in Patients with Relapsed or Refractory B-Cell Malignancies (Follicular Lymphoma, Mantle Cell Lyphoma, Diffuse Large Cell Lymphoma, or Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia

Coordinator: Becky
This study is suspended to accrual.
Protocol
HIPAA Authorization

NU Consent Form

DRUG SG040-0004
A Phase II Study of SGN-40 (anti-huCD40 mAb) in Patients with Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)

Coordinator: Simbi
Protocol Consent & HIPAA Form

DRUG BV301 (was NCI 9900)
Randomized Trial of Patient-Specific Vaccination with Conjugated Follicular Lymphoma-Derived Idiotype with Local GM-CSF in First Complete Remission: Phase III

Coordinator: David
Protocol
HIPAA Authorization

NU Consent Form

VA Consent Form

DRUG FavId-09
Phase II Trial of FavId (Patient-Specific Idiotype/KLH) and GM-CSF in Subjects Who Demonstrated Progressive Disease and Did Not Receive FavId on Study FavId-06

Coordinator: Mary Beth
Protocol
HIPAA Authorization

NU Consent Form

The following studies are Closed to Accrual (alphabetically listed)

DRUG 3129K1-100-WW
A Phase I Study of CMC-544 Administered as a Single Agent in Subjects with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

This study is closed to accrual.
Protocol
HIPAA Authorization

NU Consent Form

DRUG CA99002
Pivotal Phase II Multicenter Study of Vincristine Sulfate Liposomes Injection in Diffuse Large B-cell Non-Hodgkin's Lymphoma at Second or Later Relapse

This study is closed to accrual.
Protocol NU Consent Form

VA Consent Form

DRUG FAVID-01
Phase II Study of FavId (Tumor-Specific Idiotype-KLH) and Soluble GM-CSF Immunotherapy in Patients with Stable or Progressive Grade 1 or 2 Follicular B-Cell Lymphomas

This study is closed to accrual.
Protocol NU Consent Form

VA Consent Form

DRUG FAVID-04
Phase II Trial of Rituxan plus FavId (Tumor-Specific Idiotype-KLH) and GM-CSF Immunotherapy in Patients with Grade 1 or 2 Follicular B-Cell Lymphoma

This study is closed to accrual.
Protocol
HIPAA Authorization

NU Consent Form

Patient Diary

DRUG FavId-06
Phase III, Randomized, Double-Blind Placebo-controlled Trial of FavId™ and GM-CSF versus Placebo and GM-CSF Following Rituximab in Subjects with Follicular B-Cell Non-Hodgkin's Lymphoma

This study is closed to accrual.
Protocol
HIPAA Authorization

NU Consent Form

DRUG IDEC114-20
A Phase I/II Trial of Anti-CD80 Monoclonal Antibody (IDEC-114) Therapy for Patients with Relapsed or Refractory Follicular Lymphoma

This study is closed to accrual.
Protocol NU Consent Form

VA Consent Form

DRUG IDEC114-21
A Phase I/II Trial of IDEC-114 (Anti-CD80 Monoclonal Antibody) in Combination with Rituxan for Patients with Relapsed or Refractory Follicular Lymphoma

This study is closed to accrual.
Protocol
HIPAA Authorization

NU Consent Form

DRUG PCYC-0221
Phase II Trial of Motexafin Gadolinium (MGd) in Patients with Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

This study is closed to accrual.
Protocol
HIPAA Authorization

NU Consent Form

VA Consent Form

ECOG 1496
Randomized Phase III Study in Low Grade Lymphoma Comparing Cyclophosphamide/Fludarabine to Standard Therapy Followed by Maintenance Anti-CD20 Antibody
This study is closed to accrual.
Protocol NU Consent Form

VA Consent Form

ECOG 1497
A Phase II Study of DAB 389IL-2, an Interleukin-2 Fusion Toxin, for Previously Treated Stage II, III, and IV Follicular Low-Grade Non-Hodgkin's Lymphoma

This study is closed to accrual.
Protocol NU Consent Form

VA Consent Form

ECOG 4402
Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens for Low Tumor Burden Patients with Indolent Non-Hodgkin's Lymphoma

This study is closed to accrual.
Protocol
HIPAA Authorization

NU Consent Form

VA Consent Form

ECOG 4494
Phase III Trial of CHOP versus CHOP and Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Older Patients with Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology Non-Hodgkin's Lymphoma

This study is closed to accrual.
Protocol NU Consent Form

VA Consent Form

ECOG S9704
A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy (With Possible Late Autologous Stem Cell Transplant) for Patients with Diffuse Aggressive Non-Hodgkin's Lymphoma in the High-Intermediate and High Risk International Classification Prognostic Groups

This study is closed to accrual.
Protocol
HIPAA Authorization

NU Consent Form

NCI MSK2795
A Phase II Study of PS-341 in Low Grade Lymphoproliferative Disorders

This study is closed to accrual.
Protocol
HIPAA Authorization

NU Consent Form

NU 98H2
Phase I/II Study of Mesna, Ifosfamide, Teniposide, and Weekly Taxol (MITTen) in Relapsed Lymphoma

This study is closed to accrual.
Protocol NU Consent Form

VA Consent Form

NU 99H11
A Phase I Trial Combining IDEC-Y2B8 and High-Dose Beam Chemotherapy with Hematopoietic Progenitor Cell Transplant in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

This study is closed to accrual.
Protocol
HIPAA Authorization

NU Consent Form

NU IN01H1
Rituximab, rhuMAb VEGF (bevacizumab, Avastin), CHOP (RA-CHOP) in Combination for Patients with Untreated Diffuse Large B-Cell Lymphoma (DLCL)

This study is closed to accrual.
Protocol
HIPAA Authorization

NU Consent Form

VA Consent Form